导管式轴流泵临时心室辅助装置支持:改变儿童心脏中心的治疗模式
该研究为单中心回顾性队列,纳入2014年10月至2022年2月因急性失代偿性心力衰竭或心源性休克接受Impella导管式轴流泵支持的37例次住院(43次植入)。6个月时桥接恢复58%、桥接持久VAD 14%、桥接心脏移植14%、死亡14%。作者认为儿童导管式轴流泵支持可获得良好的1个月和6个月生存率,不良事件谱可接受。
要点
- 37例次住院共43次Impella植入,33例次(89%)使用单台装置。
- 6个月竞争结局:桥接恢复58%、桥接持久VAD 14%、桥接移植14%、死亡14%。
- 作者认为儿童导管式轴流泵支持1个月和6个月生存率良好,不良事件可接受。
核心结论
- 作者认为儿童导管式轴流泵支持可获得良好的1个月和6个月生存率,不良事件谱可接受。
研究设计与样本
- 单中心回顾性队列研究,纳入2014年10月至2022年2月因急性失代偿性心力衰竭或心源性休克接受导管式轴流泵支持的全部患者,最终队列为37例次住院、43次导管式轴流泵植入。
主要发现
- 33例次(89%)使用单台导管式轴流泵,3例次(8%)使用2台,1例次(3%)使用3台。
- 植入时中位[范围]年龄16.8[6.9-42.8]岁,体重61.1[23.1-123.8]kg,体表面积1.7[0.8-2.5]m²。
- 循环衰竭主要病因为移植物衰竭/排斥16例(43%),其次为心肌病7例(19%)、药物难治性心律失常6例(16%)、心肌炎/心内膜炎4例(11%)、先天性心脏病所致心力衰竭4例(11%)。
- 竞争结局分析显示6个月时桥接恢复58%、桥接持久VAD支持14%、桥接心脏移植14%。
- 14%的例次在6个月时死亡。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We report the largest pediatric single-center experience with an Impella (Abiomed Inc) catheter-based axial pump support. METHODS: We conducted a retrospective cohort study of all patients with acute decompensated heart failure or cardiogenic shock requiring catheter-based axial pump support between October 2014 and February 2022. The primary outcome per individual encounter (hospital admission) was defined as bridge-to-recovery, bridge-to-durable ventricular assist device support, bridge-to-cardiac transplantation, or death at 6 months after catheter-based axial pump explantation. Adverse events were defined according to the Pediatric Interagency Registry for Mechanical Circulatory Support criteria. RESULTS: Our final study cohort included 37 encounters with 43 catheter-based axial pump implantations. A single catheter-based axial pump device was used for support in 33 encounters (89%), with 2 catheter-based axial pump devices used in 3 (8%) separate encounters and 3 catheter-based axial pump devices used in 1 (3%) encounter. The median [range] age, weight, and body surface area at implantation were 16.8 [6.9-42.8] years, 61.1 [23.1-123.8] kg, and 1.7 [0.8-2.5] m2, respectively. The predominant causes of circulatory failure were graft failure/rejection in 16 patients (43%), followed by cardiomyopathy in 7 patients (19%), arrhythmia refractory to medical therapies in 6 patients (16%), myocarditis/endocarditis in 4 patients (11%), and heart failure due to congenital heart disease in 4 patients (11%). Competing outcomes analysis showed a positive outcome with bridge-to-recovery in 58%, bridge-to-durable VAD support in 14%, and bridge-to-cardiac transplantation in 14% at 6 months. Fourteen percent of encounters resulted in death at 6 months. CONCLUSIONS: We demonstrate that catheter-based axial pump support in children results in excellent 1- and 6-month survival with an acceptable adverse event profile.
引用
- Tume SC, Fuentes-Baldemar AA, Anders M, et al. Temporary ventricular assist device support with a catheter-based axial pump: Changing the paradigm at a pediatric heart center. J Thorac Cardiovasc Surg. 2022. PMID: 36681561. doi:10.1016/j.jtcvs.2022.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。